The prevalence of IgG antibodies to Helicobacter pylori was examined in 110 patients with inflammatory bowel disease (IBD) (63 ulcerative colitis, 47 Crohn's disease) and compared with 100 age and sex matched control patients. The overall prevalence ofHpylori seropositivity in the IBD patients was 22%, which was significantly less than that of 52% in the controls (p<0-002). There was no difference in prevalence between ulcerative colitis and Crohn's patients. The low seropositivity in the IBD patients resulted from a very low prevalence of 10% in those currently receiving sulphasalazine (n=40) and similarly low prevalence of 7% in those previously receiving sulphasalazine (n=30). In those receiving olsalazine or mesalazine and who had never had sulphasalazine, the prevalence of seropositivity was 45%. Further studies using 14C urea breath test and microscopy of antral biopsy specimens confirmed that the negative serology in patients receiving sulphasalazine resulted from absence of the infection rather than absence of humoral immune response to it. In six control patients with H pylori infection, a two week course of sulphasalazine (500 mg four times daily) only caused slight suppression of the 14C urea breath test.
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The low prevalence of seropositivity to Hpylori in the IBD patients as a whole resulted from the very low prevalence of 10% in the 40 patients currently receiving sulphasalazine and of 7°/0 in the 30 patients previously receiving Figure) . Patients who had never received sulphasalazine but who were receiving olsalazine (n = 5), mesalazine (n= 24) or neither (n= 11) had a prevalence of 40%, which was similar to that in the control group without IBD (Table II) .
CONFIRMATORY TESTS OF H PYLORI STATUS
The 14C urea test was negative in 22 The explanation for the absence of H pylori in the patients currently or previously receiving sulphasalazine needs to be considered. The prevalence of H pylori infection increases with age and in the Western world roughly equals the age of the patient.18 This is shown by our hospital control group with a mean age of 42 years having a prevalence of 52%. The increasing prevalence of H pyloni with age is thought to result from the fact that the infection can be contracted at any age and then becomes chronic and persists indefinitely. The very low prevalence of H pylori infection in the patients exposed to sulphasalazine probably result from the infection having been eradicated. If those receiving sulphasalazine had merely been protected from developing the infection then the prevalence would be reduced only by a percentage equivalent to the number of years taking the drug, which was a mean of 12 years. The fact that the patients who had previously received sulphasalazine but were not currently taking it had a very low prevalence of H pylori also shows that their infection had been eradicated rather than merely suppressed.
The mechanism by which sulphasalazine treatment could result in eradication of H pylori is unclear. The in vitro studies using sulphasalazine and its metabolite sulphapyridine failed to show any direct bacterial or bacteriostatic effect. In addition, 14 days of treatment with sulphasalazine only minimally suppressed the 14C urea breath test in the infected healthy volunteers, again showing little evidence of a direct effect of the drug on the bacterium.
One indirect mechanism by which sulphasalazine could lead to eradication of the infection is by its anti-inflammatory properties suppressing the antral gastritis and thus making the gastric mucosa a less hospitable environment for the organism. Exudation of plasma through the inflamed mucosa could provide H pylori with essential nutrients. The mucosal anti-inflammatory properties of sulphasalazine may with time result in suppression of the antral gastritis and thereby lead to eradication of the infection. The small but significant fall in the breath test value at the end of two weeks of sulphasalazine treatment would be consistent with a reduction in density of infection because of some resolution of gastritis. A lowered prevalence of H pylori was not apparent in patients taking pure 5-aminosalicylic acid preparations. Sulphasalazine, however, has been shown to have in vivo anti-inflammatory properties not possessed by 5-aminosalicylic acid including inhibition of B lymphocytes19 and suppression of natural killer cell activity.20 Sulphasalazine also exerts its anti-inflammatory effects outwith the large bowel as utilised in the treatment of rheumatoid arthritis.
Another indirect method by which sulpha-salazine could eradicate H pylori is by interfering with the adherence of the organism to the gastric mucosa. H pylori is known to bind to specific glycerolipid receptors on the gastric epithelial cells.21 Interestingly, sulphasalazine at concentrations present in human plasma has been found to block receptors for bacteria derived peptides on human neutrophils. 22 In addition to its use in IBD, sulphasalazine is also used as a second line agent in patients with rheumatoid arthritis. In these patients the prevalence of H pylori has been seen to be not so noticeably reduced23 and this may be explained by the fact that such patients do not receive it for so long and also all receive the enteric coated preparation, which may lack the local gastric effect. The patients attending our gastroenterology clinic were all prescribed the non-enteric coated preparation. Studies in arthritis patients, however, have noted that those receiving gold treatment have a very low prevalence of Hpylori.23 The finding that these two main second time anti-inflammatory agents both eradicate H pylori may provide a clue to their mechanism of action against the organism or even a clue to the mechanisms by which they produce their beneficial effect in arthritis. An association between gastrointestinal infection and arthritis has been recognised for many years.24 25 The original aim of this study was to find out if there might be an increased prevalence of H pylori infection in patients with IBD and thus evidence supporting a possible role of the infection in the pathogenesis of the bowel disease. Though the reduced prevalence of the infection does not support such a role it also does not refute it. The well established beneficial effects of sulphasalazine in IBD could partly result from it eradicating H pylorn and thus preventing the chronic stimulation of the mucosal immune system caused by the infection. The fact that the patients receiving olsalazine or mesalazine who had never had sulphasalazine had a prevalence of H pylori infection similar to the normal controls does not completely exclude a role for H pylori either. It is possible that our patients with IBD all had evidence of Hpylori infection on initial presentation and that sulphasalazine has lead to its eradication in nearly all patients treated whereas olsalazine and mesalazine lead to its eradication in only 50%. It will be necessary to examine H pylori status in patients presenting with IBD before commencing any such drug treatment.
In addition to the implications for the immunological basis of IBD and rheumatoid arthritis, our findings are relevant to the treatment of H pyloni. Eradication of the infection is an important challenge and it is possible that sulphasalazine might provide a new approach to it, possibly by being given in conjunction with another antibiotic. 
